HF
LUCD icon

HRT Financial’s Lucid Diagnostics LUCD Stock Holding History

HRT Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,308
Closed -$24K – 3178
2025
Q1 		$24K Sell
16,308
-43,332
-73% -$52K ﹤0.01% 2290
2024
Q4 		$48K Buy
+59,640
New +$52.6K ﹤0.01% 2115
2024
Q2 		– Sell
-63,035
Closed -$51K – 2711
2024
Q1 		$51K Buy
+63,035
New +$81.8K ﹤0.01% 1929

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

HRT Financial's LUCD Position: Q2 2025 in Review

HRT Financial sold out of Lucid Diagnostics (LUCD) in Q2 2025, closing a stake of 16,308 shares — an estimated $24K sold.

HRT Financial first reported a position in LUCD in Q1 2024 and held it in 3 quarters. The position peaked at $51K in Q1 2024. 72 funds tracked by Wall St. Rank hold LUCD as of Q2 2025.

  • HRT Financial reported no remaining Lucid Diagnostics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 16,308 Lucid Diagnostics shares in Q2 2025, an estimated $24K.
  • HRT Financial first reported a position in Lucid Diagnostics in Q1 2024 and held it in 3 quarters.
  • HRT Financial's Lucid Diagnostics position peaked at $51K in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.